Recipharm achieves new ISO 45001 certification to support sustainability efforts
Recipharm, the contract development and manufacturing organisation (CDMO), has achieved the new ISO 45001 certification at its Wasserburg facility in Germany. The certification is developed from an earlier certification according to OSHAS 18001 and a result of the Wasserburg facility’s programme to enhance its sustainability and safety efforts.
Following an audit in January 2019, the facility, which is one of Recipharm’s sterile manufacturing operations, was recognised for its high calibre occupational health and safety management systems.
ISO 45001 is the new working protection standard from the International Organisation for Standardisation (ISO), developed to improve employee safety, reduce workplace risk and create better working conditions globally.
Erik Haeffler, VP of Manufacturing Services and Head of sustainability said, “Recipharm is committed to the ongoing development of its sustainability standards. Achieving ISO 45001 at our first site demonstrates that we can perform to the highest standards when it comes to occupational health and safety.”
“We now start the roll-out across our other facilities as we work towards ensuring we have state-of-the-art management systems in place to manage not only occupational health and safety, but also other areas such as the environmental impact.”
Recipharm has more projects planned throughout 2019 focusing on employee health and safety, environmental protection and improving energy efficiency to ensure continuous improvement and compliance.
Recipharm’s facility in Wasserburg is part of the company’s centre of excellence for lyophilisation in vials using highly automated state-of-the-art equipment. The site’s large-scale freeze-drying capabilities were also extended last year following a EUR 32 million investment.
Erik Haeffler, Vice President Manufacturing Services & Head of Sustainability, firstname.lastname@example.org, +46 8 6025 285
For media enquiries, please contact Kate Hindhaugh at ramarketing: email@example.com, + 44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com